Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)

Dexamethasone, Cytarabine, Cisplatin and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP-cHL)

A clinical study of safety and efficacy of treatment with Nivolumab and DHAP in patients with relapsed/refractory Hodgkin's lymphoma

A Clinical Study of Safety and Efficacy of Treatment With Nivolumab and Dexamethasone, Cytarabine and Cisplatin (DHAP) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Inclusion Criteria:

• Signed informed consent
• Histologically confirmed Hodgkin's lymphoma
• Measurable disease (at least one lesion that can be accurately measured in at least two dimensions with spiral CT scan, min > 15 mm in the longest diameter or > 10 mm in the short axis)
• World Health Organization (WHO) performance status < 2
• Relapsed or refractory to at least one prior treatment line
• No prior therapy with DHAP or Nivolumab
• No severe concurrent illness

Exclusion Criteria:

• History of HIV
• Active Hepatitis B or Hepatitis C infection
• Uncontrolled infection (requiring intravenous treatment) at the time of enrollment
• Pregnancy or breastfeeding
• Somatic or psychiatric disorder making the patient unable to sign informed consent
• Active or prior documented autoimmune disease requiring systemic treatment
• No receiving a live vaccine within 30 days prior to first dose of nivolumab
• History of non-infectious pneumonitis that required steroids
• Other malignancy